Motion sickness research has been accelerating. The next decade will bring pharmaceutical advances, AI-personalized digital therapeutics, neuromodulation, and precision medicine. Here's what's actually coming.
Motion sickness research has been quietly accelerating. For most of the 20th century, treatment meant antihistamines that made you drowsy — and that was it. The last decade brought vestibular rehabilitation into the mainstream, produced the first strong evidence for visuospatial training, saw the emergence of digital therapeutics, and began grappling with entirely new triggers created by VR and autonomous vehicles.
The next decade will bring even faster change. This article examines the major threads of motion sickness treatment development — the research, the pharmaceutical pipeline, the digital therapeutics frontier, and what you can realistically expect from the field by 2030.
A note on scope: This article focuses on how treatment is evolving — the treatment innovation landscape. The emerging triggers creating new motion sickness problems (self-driving cars, space tourism, mixed reality) are covered separately in the Future of Motion Sickness guide.
Section 1: The pharmaceutical frontier
The current pharmaceutical options for motion sickness are remarkably old. Dimenhydrinate was developed in 1949. Meclizine entered use in the 1950s. Scopolamine patches, the most sophisticated current option, have been available since 1979. All are effective. All have significant limitations.
Why current medications have a ceiling
First-generation antihistamines (dimenhydrinate, meclizine) work by blocking histamine H1 receptors involved in the vomiting reflex pathway, but histamine is a broad neurotransmitter, so blocking it causes sedation, cognitive impairment, and dry mouth as side effects. They're blunt instruments.
Scopolamine is more targeted — it blocks muscarinic acetylcholine receptors in the vestibular nuclei — but still produces side effects including dry mouth, blurred vision, and in higher doses, hallucinations and confusion. The patch delivery system reduces peak blood levels and therefore side effects, but doesn't eliminate them.
The fundamental limitation of all pharmaceutical approaches: they address symptoms, not susceptibility. Even a perfect medication still requires you to take it every time you encounter a triggering situation. For detailed comparison of medication versus brain training approaches, see our complete analysis.
New-generation compounds
The most active pharmaceutical research in motion sickness is focused on two directions:
Selective receptor targeting: Identifying which specific receptor subtypes in the vestibulo-cerebellar pathway are most critical to the nausea response, and developing compounds that block those receptors selectively. The goal is anti-emetic efficacy without the broad neurotransmitter blockade that causes sedation and cognitive impairment.
NK1 receptor antagonists: The same class that produced effective chemotherapy anti-emetics (aprepitant, fosaprepitant). These block substance P in the vomiting center more selectively than antihistamines. Research into their efficacy for motion sickness specifically is ongoing.
Cannabinoid research: THC and CBD derivatives have shown early promise for nausea reduction in several contexts. CB1 receptor agonism in the brainstem appears to modulate the emetic response with less cognitive impairment than current options for some patients. Still early-stage for motion sickness specifically.
Precision medicine: matching the drug to the patient
Approximately 35 genetic variants have been associated with motion sickness susceptibility. The next step in pharmaceutical development is understanding which genetic profiles predict response to which medications — enabling a physician to prescribe based on your genetic susceptibility pattern rather than trial-and-error.
Section 2: Advances in digital therapeutics
Digital therapeutics will be the most significant treatment development for motion sickness over the next decade — not because the technology is flashier than pharmaceuticals, but because the motion sickness problem is fundamentally a training problem, and digital delivery solves the major barriers to training: access, adherence, and personalization.
FDA prescription digital therapeutics pathway
The FDA's approval of reSET (substance use disorder), EndeavorRx (ADHD), and other prescription digital therapeutics established the regulatory pathway for software as a medical treatment. Vestibular rehabilitation digital therapeutics are advancing through this pathway — enabling physician prescribing and insurance coverage for app-based vestibular training programs.
This is meaningful for patients: it moves digital vestibular rehabilitation from consumer wellness (pay out of pocket, no medical supervision) to medical care (physician involvement, insurance coverage, documented outcomes). For a deeper look at the current regulatory landscape, see our digital vestibular rehabilitation guide.
AI-personalized protocols at scale
The first generation of digital vestibular training programs deliver structured protocols to all users with some personalization based on symptoms and triggers. The next generation will use machine learning trained on population-level outcome data to identify optimal exercise sequences for each individual.
The difference is significant. A protocol optimized for your specific susceptibility profile, trigger pattern, and response to training will outperform a well-designed generic protocol. As platforms accumulate outcome data from hundreds of thousands of users, the personalization models will improve continuously.
Biomarker integration
Wearables can now detect early physiological signs of nausea — heart rate variability changes, galvanic skin response increases, peripheral temperature changes — that precede conscious symptom awareness by several minutes. Integrating these signals into training programs enables real-time protocol adjustment: the system detects that you're approaching your threshold and adjusts the exercise to a less challenging level before you feel sick, keeping you in the optimal training zone rather than triggering dropout.
VR-native vestibular training
VR headsets create precisely controllable visual environments that make them uniquely powerful for habituation training. The ability to present specific visual-vestibular conflicts at calibrated doses — a virtual ship deck that moves at exactly the amplitude you're habituating to, presented to both visual fields simultaneously — is dramatically better than any non-VR alternative for structured habituation. Major healthcare systems are beginning to incorporate VR vestibular training into clinical protocols.
Gamification and long-term adherence
The evidence for vestibular training efficacy is based on consistent completion of training programs. Adherence — actually doing the exercises daily for 14–30 days — is the limiting factor for many patients. Games that deliver the therapeutic stimulus as a byproduct of gameplay solve this problem by making the training intrinsically engaging. This is actively being developed by several companies at the intersection of game design and digital health.
Section 3: Neuromodulation and direct interventions
Galvanic vestibular stimulation (GVS) — from research to clinical use
GVS, which uses small electrical currents to modulate vestibular nerve activity, has demonstrated significant efficacy in research settings. The gap between research results and consumer products is calibration — effective GVS requires precise parameters matched to the individual. Clinical-grade GVS systems are used in research; consumer-accessible versions are emerging but still working through the calibration challenge.
The trajectory: clinical GVS devices will likely receive FDA clearance for specific vestibular conditions within the next few years, followed by consumer-accessible versions as the technology matures.
Transcranial magnetic stimulation (TMS)
Non-invasive brain stimulation targeting the posterior parietal cortex and vestibular cortex areas has shown early promise for enhancing vestibular processing and accelerating adaptation. TMS is already in clinical use for depression and migraine; the vestibular application is earlier-stage but mechanistically plausible.
Closed-loop neurofeedback systems
Devices that monitor vestibular processing signals continuously and deliver interventions (stimulation, visual adjustments, movement cues) when early indicators of sensory conflict are detected. The engineering challenge is building systems responsive enough to intervene before symptoms develop rather than in response to them.
Pharmacological enhancement of neuroplasticity
An approach borrowed from emerging PTSD and anxiety treatment research: administer a compound that enhances synaptic plasticity during the training window, making the vestibular adaptation process more efficient. The drug isn't treating the motion sickness directly — it's making the brain better at learning from the training. Early human studies are underway; this is likely a 5–10 year timeline for clinical availability.
Section 4: New understanding of the underlying biology
The fundamental biology of motion sickness is better understood than it was a decade ago, and the knowledge gaps that remain are narrowing.
Gut-brain axis: Nausea has a gastrointestinal component that interacts with the vestibular-central pathway. Research on the gut microbiome's role in nausea susceptibility is expanding. Whether this will yield practical interventions for motion sickness specifically is unclear, but the expanding understanding of nausea biology informs drug development across all causes.
Hormonal influences: Women have consistently higher motion sickness susceptibility than men across every measurement approach and culture studied. The gap is largest during the first trimester of pregnancy and at certain phases of the menstrual cycle. The mechanisms — likely involving estrogen's effects on vestibular receptor sensitivity and central processing — are being actively researched, with implications for treatment personalization across sex and hormonal therapy status.
Genetic architecture: As noted above, ~35 genetic variants have been associated with susceptibility. The research is moving toward understanding the specific pathways each variant affects, enabling precision medicine approaches. For more on individual susceptibility differences, see why some people get motion sick and others don't.
Developmental trajectory: Motion sickness typically peaks in childhood (ages 4–12), then gradually declines through adolescence. Understanding the developmental mechanisms — which appear to involve the maturation timeline of visuospatial processing relative to vestibular sensitivity — may inform both pediatric treatment approaches and adult susceptibility patterns.
Section 5: What treatment will look like by 2030
Projecting specific timelines in emerging fields involves uncertainty, but the trajectory of multiple research threads allows reasonable near-term predictions.
Digital-first treatment will be standard. By 2030, motion sickness treatment will routinely begin with an app-based or telehealth-delivered assessment and protocol rather than a pill or an in-person clinic visit. The combination of evidence, access, and cost-effectiveness will make this the default first step.
Pre-travel preparation will be normalized. People will "train up" for cruises, long road trips, and AV commutes the way athletes train for events. The concept of arriving at a triggering situation with a prepared vestibular system — rather than hoping for the best or relying on medication — will be mainstream.
Insurance coverage for digital therapeutics will be established. The PDT regulatory pathway will have matured, and at least some digital vestibular rehabilitation programs will have insurance coverage in major markets.
Non-sedating pharmaceutical options will exist. First clinical approvals of next-generation anti-motion-sickness compounds without the sedation profile of current antihistamines are likely within this window.
AV preparation will be a product category. Autonomous vehicle manufacturers or ride-hailing operators will either offer or partner on pre-subscription vestibular preparation programs as part of the product experience.
Space tourism preparation will be structured. Commercial space companies will have developed or adopted standardized pre-flight vestibular preparation protocols for paying customers.
The bottom line
Motion sickness isn't going to be "solved" in a traditional sense — the underlying biology isn't changing. What's changing is how accessible, personalized, and effective treatments are. The gap between "I have to just live with this" and "I have a clear treatment path" is closing rapidly.
Motion Relief is built on the insight that the brain is trainable — and that this training produces resilience that transfers across current and future triggers. Whatever new motion technology emerges over the next decade, the people who have trained their vestibular systems will encounter it more comfortably.
I think about the product not as a solution to today's motion sickness problem, but as a foundation for every motion context you'll encounter going forward. Autonomous vehicles, mixed reality glasses, commercial space travel — the same trained brain handles all of them better. That's the durable value of what we're building.
The person who starts brain training today will be years ahead of the curve — building resilience that will benefit them across every current and future trigger. The future of motion sickness treatment is one where you're not stuck with it.
Find Out What's Causing Your Motion Sickness
Take our free 2-minute assessment to get a personalized motion sickness profile — and a science-backed plan to reduce your symptoms.
This article is part of the Future of Motion Sickness guide. For the technology landscape specifically, see Motion Sickness Technology: The Emerging Tech Landscape. For digital vestibular rehabilitation in clinical context, see Digital Vestibular Rehabilitation.
Sources
- Golding JF, Gresty MA. "Pathophysiology and treatment of motion sickness." Current Opinion in Neurology. 2015;28(1):83–88.
- Smyth J, et al. "Visuospatial training reduces motion sickness susceptibility in healthy adults." Experimental Brain Research. 2021;239(4):1097–1113.
- Heaton K, et al. "Genetic associations with motion sickness susceptibility." BMC Medical Genomics. 2014;7:7.
- Keshavarz B, et al. "Galvanic vestibular stimulation (GVS) as a tool to induce, modify, and suppress motion sickness." Frontiers in Neurology. 2020;11:601.
- Lackner JR. "Motion sickness: more than nausea and vomiting." Experimental Brain Research. 2014;232(8):2493–2510.
Discover What's Really Behind Your Motion Sickness
Our free assessment identifies your motion sickness type and susceptibility level — then gives you a personalized plan based on your results.
Know your motion sickness triggers and severity
Get a personalized symptom reduction plan
See which training exercises match your profile
Free — takes less than 2 minutes
